July 17, 2008 - International Stem Cell Corporation and Novocell, Inc. Collaborate to Test Human Parthenogenetic Stem Cells for production of Pancreatic Islet Cells that may be useful in the Treatment of Diabetes — International Stem Cell Corporation (OTCBB: ISCO) announced a collaboration with Novocell Inc. (La Jolla, CA) to use ISCO’s human parthenogenetic stem cell lines for differentiation to Human pancreatic islet cells. The studies will be directed by Nikolay Turovets, PhD, Director, Research and Therapeutic Development at ISCO in collaboration with Novocell scientists.
ISCO’s unique stem cells offer a solution for two of the most difficult problems facing stem cell therapy. They are the first step in preventing the rejection of implanted cells by the patient’s own immune system and they provide an alternative to embryonic stem cells that does not involve destroying human embryos...
...Novocell has developed technology to direct embryonic stem cells to become pancreatic islet cells that have been shown to be effective in treating diabetes in animals. The combined technologies of the two companies may therefore result in therapeutic cells with improved immune properties for eventual treatment of larger segments of the diabetic population.
A description of ISCO’s human parthenogenetic stem cells and their potential to improve transplantation was reported in ISCO’s peer review paper published December 19, 2007 in the online edition of Cloning and Stem Cells Journal... International Stem Cell Corporation's Press Releases -
Blog Archive
-
▼
2008
(233)
-
▼
July
(23)
- MicroIslet : Safety and Efficacy Data Update
- CombinatoRx : Progress in Key Programs at 2008 R&D...
- Metabolon : Collaboration with the University of T...
- Santarus and Depomed : U.S. Promotion Agreement fo...
- International Stem Cell and Novocell : Collaborati...
- XOMA 052 Phase 1 Data to be Presented At European ...
- Hollis Eden Pharmaceuticals : Phase II Clinical Tr...
- Genaera : Data on Mechanism of Inhibition of PTP-1...
- Emisphere Technologies : Data From Independent Cli...
- Animas Corporation : OneTouch Ping Glucose Manage...
- Echo Therapeutics : Clinical Study of Its Symphony...
- BodyTel : to Launch GlucoTel System in August
- Axis-Shield : AFINION HbA1c patent granted in USA
- AgaMatrix : New WaveSense Presto and Pro Glucose M...
- ARKRAY USA : National Launch of GLUCOCARD X-METER
- Georgetown University Teams with Gentag and SAIC :...
- Emisphere : License Agreement With Novo Nordisk to...
- Debiotech and STMicroelectronics : First Prototype...
- Abbott : Phase III Sub-Group Analysis Shows Invest...
- ProStrakan : Novel Testosterone Gel Significantly ...
- Isis : Robust Drug Portfolio for Diabetes and Obes...
- Sangamo BioSciences : Presentation of Phase 1b ZFP...
- HemoCue : First FDA CLIA Waiver in Diagnostics Ind...
-
▼
July
(23)
Friday, July 18, 2008
International Stem Cell and Novocell : Collaboration to Test Human Parthenogenetic Stem Cells for production of Pancreatic Islet Cells...
Libellés :
ISCO [International Stem Cell Corporation],
Novocell